Compare Expeditors International of Wshngtn Inc (EXPD) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Zoetis Inc — how do they compare? Expeditors International of Wshngtn Inc trades at $194.43 (market cap $25.18B), while Zoetis Inc trades at $74.24 (market cap $30.20B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 43 Days and Zoetis Inc for 70 Days on average.
| EXPD | ZTS | |
|---|---|---|
Market Cap | $25.18B | $30.20B |
Volume | 1,003,557 | 6,175,327 |
Sector | Industrials | Health |
52-Week High | $194.12 | $147.53 |
52-Week Low | $113.13 | $69.09 |
Typical Hold Time | 43 Days | 70 Days |
Enterprise Value | $24.72B | $37.76B |
Dividend Yield | 0.84% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $190.85, down 0.5% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 expected at $2.20 EPS. Revenue growth is steady, rising from $10.6B in 2024 to a projected $12.0B in 2026, while net income margins remain stable around 7.6%. Recent news highlights efficiency initiatives and airfreight demand as positive catalysts.
Outlook is mixed: strong profitability and earnings beats support upside, but a high P/E of 28.2 suggests premium valuation risks. Analyst consensus is cautious with 63.6% hold ratings, and the consensus price target of $179.43 implies potential downside. Key risks include freight market volatility and execution challenges amid economic uncertainty.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed earnings performance, having beaten estimates in Q2 2026 but missing in Q1. Despite recent headwinds in U.S. companion animal sales, the company maintains strong profitability with 71.67% gross margins and 27.69% net income margins. Analyst consensus remains positive with a $87.33 price target, though technical indicators suggest near-term pressure with support at $70-$71.
Zoetis presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 9.4) and robust fundamentals, though near-term risks include competitive pressures in pet medications and weakening U.S. veterinary clinic traffic. The company's international and livestock segments show resilience, supporting long-term growth potential despite current market skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
